Abstract | OBJECTIVE: STUDY DESIGN: A randomized, multicenter study was conducted on 192 women with endometriosis. Patients received nafarelin or leuprolide for six months and were followed for up to six months after treatment. QOL was defined by seven items, including symptom severity, daily activities, pain medication use and need for bed rest. RESULTS: No significant differences were found at baseline between treatments for patients with mild, moderate or no endometriosis symptoms. Those with severe symptoms of endometriosis at baseline and taking nafarelin had a significantly greater improvement in QOL at the last posttreatment visit than those receiving leuprolide (P < .01). Nafarelin was associated with significantly fewer days with moderate or severe hot flashes than leuprolide during treatment (P < .05) and with significantly fewer moderate or severe hypoestrogenic symptoms overall at three months of treatment (P < .05). Additionally, poorer QOL was significantly associated with hypoestrogenic and endometriosis symptoms. CONCLUSION:
|
Authors | S Z Zhao, L A Kellerman, C A Francisco, J M Wong |
Journal | The Journal of reproductive medicine
(J Reprod Med)
Vol. 44
Issue 12
Pg. 1000-6
(Dec 1999)
ISSN: 0024-7758 [Print] United States |
PMID | 10649809
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Analgesics
- Fertility Agents, Female
- Hormones
- Nafarelin
- Leuprolide
|
Topics |
- Adult
- Analgesics
(therapeutic use)
- Bed Rest
- Endometriosis
(drug therapy, pathology)
- Female
- Fertility Agents, Female
(adverse effects, therapeutic use)
- Hormones
(adverse effects, therapeutic use)
- Hot Flashes
(chemically induced)
- Humans
- Leuprolide
(adverse effects, therapeutic use)
- Middle Aged
- Nafarelin
(adverse effects, therapeutic use)
- Pain
(etiology)
- Quality of Life
- Severity of Illness Index
- Treatment Outcome
|